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Objective: We sought to determine whether concurrently high levels of HDL cholesterol and CRP pre-
dict initial cardiovascular events in women, and to assess additional risk involving two genes encoding
proteins involved in reverse cholesterol transport.
Methods: A graphical approach identiﬁed high-risk subgroups in a population-based female cohort.
Polymorphism-associated riskwas assessed for CETP (TaqIB [rs708272]) and LPL (D9N [rs1801177]) using
multivariable analysis adjusted for clinical parameters and biomarkers.eywords:
ipoprotein lipase
9N polymorphism
holesteryl-ester transfer protein
aqIB polymorphisms
-reactive protein
Results: A high HDL-C/high CRP high-risk subgroup was identiﬁed. Multivariable modeling revealed D9N
as predicting subgroup cardiovascular disease risk directly (minor allele-carriers versus major allele
homozygotes: HR 5.16, 95% CI 1.43–18.54, p=0.012) and through interaction with TaqIB (highest risk
in minor allele carriers of both polymorphisms).
Conclusions: In women with high HDL-C and high CRP levels, an LPL polymorphism associated with risk
and interactedwith aCETPpolymorphismsuch that thehighest risk occurred in subjectswith presumably
th prDL cholesterol
ardiovascular disease
decreased activities of bo
. Introduction
Concurrently high levels of HDL cholesterol (HDL-C) and C-
eactive protein (CRP) have recently been reported to be associated
ith increased cardiovascular disease (CVD) risk in men initially
ithout CVD [1] and in postinfarction patients [2]. Furthermore,
n postinfarction patients, a variant of the cholesteryl-ester trans-
er protein (CETP) gene associated with decreased CETP mass and
ctivity has been reported to predict risk in patientswith highHDL-
and CRP levels [2]. This ﬁnding is consistent with impaired early
hases of reverse cholesterol transport (RCT) as possibly playing a
ole in the observed risk-association by facilitating dysfunctional
ransformation of HDL.To investigate this notion further, the current study aimed:
o replicate the ﬁnding of a similar high HDL-C/high CRP high-
isk subgroup in women without CVD and to explore in men and
omen, initially without CVD, the effect on risk of decreased activ-
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ity of CETP and lipoprotein lipase (LPL), proteins both involved
in HDL particle remodeling. To do this, we used outcome event
mapping, a graphical exploratory data analysis tool for identify-
ing high-risk subgroups [1–3], and Cox multivariable proportional
hazards regression in conjunctionwith activity probes consisting of
genetic polymorphismsofCETP (TaqIB [rs708272]) [4] and LPL (D9N
[rs1801177]) [5] in male and female cohorts of the Prevention of
Renal andVascular End-StageDisease (PREVEND) population study
[6].
2. Methods
2.1. Study population
The study group [1] comprised a cohort (N=8592) of PREVEND
[6], a prospective longitudinal study assessing albuminuria in pre-
dicting cardiovascular [7] and renal [8] disease. PREVEND was
approved by the medical ethics committee of the University of
Open access under the Elsevier OA license.Groningen, The Netherlands. PREVEND excluded insulin-using dia-
betics and pregnant women. Further exclusions for the present
work included history of diabetes mellitus, renal disease, previous
CVD, and incomplete laboratory results. Subjects with CRP levels
≥10mg/Lwere excluded (to avoid confounding by inter-current ill-
3 sclerosis 214 (2011) 373–376
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Table 1
Signiﬁcant (p<0.10) univariate Cox regression results for clinical parameters,
biomarkers, and polymorphisms (TaqIB of CETP and D9N of LPL) in the high-risk
subgroups of female subjects.
Marker Cox regression results
Hazard ratioa 95% CI p
HR1 (low HDL-C/high CRP)
Ageb 2.82 1.84–4.33 <0.001
BMIb 1.35 1.02–1.80 0.039
Hypertensionb 7.22 2.53–20.62 <0.001
HDL-C 0.68 0.50–0.93 0.014
HDL-C/apoA1 0.37 0.21–0.68 0.001
Triglycerides 1.39 1.12–1.72 0.003
apoB 1.33 1.04–1.71 0.024
Cholesterolb 1.71 1.26–2.31 <0.001
Glucose 1.29 1.09–1.52 0.003
TaqIb (CETP) 0.99 0.47–2.07 0.98
HR2 (high HDL-C/high CRP)
Ageb 2.69 1.49–4.86 0.0011
BMIb 1.59 1.07–2.37 0.022
Hypertensionb 4.85 1.37–17.18 0.014
CRP 1.51 0.95–2.41 0.082
Triglycerides 1.51 1.10–2.05 0.01
apoB 1.69 1.25–2.29 <0.001
apoB/apoA1 1.88 1.30–2.73 <0.001
Cholesterol 1.67 1.30–2.13 <0.001
Glucose 1.45 1.14–1.83 0.002
TaqIb (CETP) 2.62 0.59–11.69 0.2174 J.P. Corsetti et al. / Athero
ess); there was no exclusion based on HDL-C levels. Sub-cohorts
f men (N=3405) andwomen (N=3619) resulted (see Supplement
Methods).
.2. Blood markers and genotyping
Overnight fasted blood samples collected after 15minutes of
est were stored at −20 ◦C prior to analysis [9] (see Supplement –
ethods). Genotyping of TaqIB (CETP) was performed as described
reviously [9]. Genotyping of D9N (LPL), was performed using
aqMan-MGB probes, primer, SDS 2.0 genotype calling software,
nd ABI 7900HT apparatus (Applied Biosystems, Applera Neder-
and, Nieuwerkerk aan de IJssel, The Netherlands).
.3. Outcomes
Outcomes were combined incidence of CVD mortality and
ost-baseline hospitalisation [1]. Cardiovascular events included:
cute MI, acute and subacute ischemic heart disease, coronary
rtery bypass grafting, and percutaneous transluminal coronary
ngioplasty. Median follow-up was 7.6 years (see Supplement –
ethods).
.4. Statistical analyses
Outcome event mapping [1–3] was used to identify high-risk
ubgroups (see Supplement – Methods). Statistica 9.0 (Stat-
oft, Inc., Tulsa, OK) was used for statistical and graphical
nalyses. Statistical tests (p<0.05) included Pearson correlation,
ann–Whitney U, Kruskal–Wallis with Bonferroni correction, chi-
quare,Kaplan–Meierwith log-rankstatistic, andmultivariableCox
roportional hazards regression (biomarkers treated as continuous
ariables; polymorphisms treated as minor allele carriers versus
ajor allele homozygotes).
. Experimental results
.1. Study population
Qualitative identiﬁcation in female subjects of two high-
isk subgroups was reported previously [1]. Subsequent analysis
Supplement – Experimental results) revealed 879 subjects in a low
DL-C/highCRPhigh-risk subgroup (henceforthHR1); 508 subjects
n a high HDL-C/high CRP subgroup (henceforth HR2); and 2232
ubjects in a lower risk background subgroup (henceforth BG). Sub-
ects in HR1 versus HR2 (Supplement – Table 1) were older, more
ypertensive, havemoreMSand less alcohol use. Additionally, they
emonstrated higher levels of cholesterol, triglycerides, nonHDL-C,
lucose, apoB and apoB/apoA1 ratio, and lower HDL-C, apoA1, and
DL-C/apoA1 ratio, a rough measure of HDL particle size.
Correlation between HDL-C and triglyceride levels was used
o indirectly assess HDL particle remodeling. Correlation coefﬁ-
ients (all signiﬁcant)were: BG,−0.24;HR1,−0.29; andHR2,−0.15.
esults of pairwise comparisons were: BG/HR1 (p=0.16), BG/HR2
p=0.057), and HR1/HR2 (p=0.0074). Thus in HR2, the magnitude
f inverse correlation between HDL-C and triglycerides was signif-
cantly less than in HR1.
.2. Genotype distributions
The TaqIB polymorphism (CETP) in females was in
ardy–Weinberg equilibrium; the D9N polymorphism (LPL)
as not (for details and likely explanation, see Supplement –
xperiment results). Signiﬁcant differences (p<0.01) in blood
arkers (HDL-C, apoA1, triglyceride, apoB, and total cholesterol)
ccording to the polymorphisms (minor allele carriers versusD9N (LPL) 6.04 1.69–21.67 0.0057
a Hazard ratio for continuous variables expressed per SD unit.
b Parameters adjusted for in multivariable models.
major allele homozygotes) were for TaqIB: in HR1 and HR2, none;
in BG, higher HDL-C and apoA1. For D9N, there were none.
3.3. Univariate biomarker and polymorphism risk within
subgroups
Table 1 gives univariate signiﬁcant Cox regression results for
the high-risk subgroups. For TaqIB, the hazard ratio in both sub-
groupswasnon-signiﬁcant; although forHR2, therewasa tendency
towards signiﬁcance. For D9N, in HR2 the hazard ratio was signiﬁ-
cant; inHR1, Coxanalysiswasnot applicable asminor allele carriers
had no outcomes.
3.4. Polymorphism multivariable risk within subgroups
Multivariablemodeling adjusted for signiﬁcant clinical parame-
ters andbiomarkers (HR1–age,BMI, hypertension, andcholesterol;
HR2 – age, BMI, and hypertension; Supplement – Experimental
results) was performed as a function of the polymorphisms. In
HR1, TaqIB was non-signiﬁcant; D9N analysis was excluded as
noted above. In HR2, D9N remained signiﬁcant with greater risk
for minor allele-carriers (hazard ratio 5.16, 95% CI 1.43–18.54,
p=0.012); TaqIB tended towards signiﬁcance (hazard ratio 2.15,
95% CI 0.48–9.73, p=0.32).
To assess potential effects on HR2 of enrichment in PREVEND
with albuminuric subjects, UAE and serum creatinine were forced
into multivariable models. The D9N polymorphism remained sig-
niﬁcant. Additionally, a sensitivity analysis was performed on a
PREVEND female sub-cohort not enriched with albuminuric sub-
jects. High-risk subgroups similar to HR1 and HR2 resulted. In the
corresponding HR2 subgroup, D9N tended towards signiﬁcance
(hazard ratio 5.02, 95% CI 0.59–42.70, p=0.14).3.5. Polymorphism interaction analysis within subgroups
To assess risk-associated interaction between the polymor-
phisms, Cox models were run including an interaction term.
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Fig. 1. Kaplan–Meier plots for female subjects in the high HDL-C/high CRP high-risk
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mubgroup (HR2) showing outcome events over time. Signiﬁcant interaction between
he D9N polymorphism of LPL and the TaqIB polymorphism of CETP (p=0.0002) is
emonstrated in that carriers of theminor alleles of both polymorphisms (light line)
how greater outcome events than remaining subjects (heavy line).
nteraction was signiﬁcant in HR2 but not in HR1. Fig. 1 illustrates
he interaction in HR2 through Kaplan–Meier curves for minor
llele carriers of both polymorphisms versus remaining subjects
p=0.0002).
.6. Polymorphism analyses in male PREVEND subjects
Characterization ofmale PREVENDsubjects and identiﬁcationof
igh-risk subgroups similar to females have been reported previ-
usly [1]. Similar analyses (Supplement – Experimental results) as
bove in males revealed non-signiﬁcance for both polymorphisms
n the corresponding high-risk subgroups.
. Discussion
Results of the current study demonstrate in women initially
ithout CVD a high-risk subgroup at high levels of HDL-C and CRP,
imilar to ﬁndings in men [1] and postinfarction patients [2]. Fur-
hermore, investigations using multivariable risk-modeling within
he subgroup with genetic markers to probe effects of decreased
ctivities of CETP and LPL demonstrated D9N as a signiﬁcant pre-
ictor of risk, and a trend towards signiﬁcance for TaqIB. Moreover,
nteraction between D9N and TaqIB was signiﬁcant with highest
isk occurring in minor allele carriers of both polymorphisms, in
ach case, the allele reportedly associated with decreased protein
ctivity [4,5]. An additional ﬁnding in women, as in men [1], was
dentiﬁcation of a secondhigh-risk subgroup at lowHDL-C andhigh
RP levels enriched with metabolic syndrome subjects. This sub-
roup demonstrated a higher level of inverse correlation of HDL-C
ith triglycerides than the high HDL-C subgroup, a ﬁnding poten-
ially indicative of less efﬁcient HDL particle remodeling in the high
DL-C subgroup.
Corresponding ﬁndings were not seen in men. This may be
elated to the overall higher event rate in men (7.74%) versus
omen (2.95%) that when analyzed speciﬁcally in the context of
vent rates for D9N revealed similar values forminor allele carriers
men – 12.50%; women – 14.29%), but dissimilar values for major
llele homozygotes (men– 7.62%;women–2.43%). Thus, it appears
hat lack of D9N associated risk in men stems not from differences
n the higher outcome rates of minor allele carriers but rather from
he relativelyhigher risk inmajor allele homozygotes ofmenversus
omen.
LPL [10,11] is involved with triglyceride-rich lipoprotein
etabolism and lipoprotein remodeling including HDL [12,13].sis 214 (2011) 373–376 375
Consistent with our study, the reduced-activity minor allele of
D9N is generally associated with increased CVD risk [5]. D9N-
associated risk, especially in conjunction with TaqIB, suggests a
role for altered HDL remodeling in pro-atherogenic transformation
of HDL, a process likely potentiated by the inﬂammatory environ-
ment deﬁning the subgroup. In this regard, high CRP may play
a direct role in this transformative process. Recent reports [14]
detail direct effects of CRP potentially relating to HDL transforma-
tion including myeloperoxidase release from human neutrophils,
superoxide anion production via up-regulation of NAD(P)H oxidase
inhuman foamcells; and superoxide release fromratmacrophages.
These effects could potentially link CRP to HDL dysfunction given
recent reports of loss ofHDLanti-atherogenic functionality through
myeloperoxidase-mediated apoA1 oxidation [15]. Moreover like
LDL [14], HDL outer layer phospholipids could be oxidized by CRP-
mediated elaboration of oxidative species generating CRP binding
sites onHDLparticles that, again like oxidized LDL [14], could result
in subsequent macrophage uptake of CRP-bound HDL.
Limitations in the current study included study population
over-sampling with high-UAE subjects; however, ﬁndings regard-
ing D9N-associated risk appeared little affected when UAE and
creatinine were forced into multivariable models and when sen-
sitivity analysis of a sub-cohort without albuminuric enrichment
also gave similar results. Further study limitations related to the
lack of evidence for the causal role of inﬂammation and oxidative
stress in HDL dysfunctional transformation and lack of evidence for
decreased activity of CETP and LPL in minor allele carriers. Future
studies should be designed to address these issues.
The current study demonstrated in a population of women ini-
tially without CVD a high-risk subgroup deﬁned by concurrently
high levels of HDL-C and CRP. This subgroup was similar to high-
risk subgroups previously identiﬁed in men initially without CVD
[1] and in postinfarction patients [2]. Among high-riskwomen, car-
riage of the less active allele of D9N (LPL) was found to associate
with risk and with simultaneous carriage of the less active allele
of TaqIB (CETP) to intensify risk. We conclude that compromised
early stages of RCT involving alterations in HDL particle remodel-
ing likely play a role in establishing risk in women with high levels
of HDL-C and CRP.
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